Evofem Biosciences (EVFM) Stock Statistics & Valuation Metrics

Evofem Biosciences has a market cap or net worth of $1.15M. The enterprise value is $66.39M.

Evofem Biosciences has 132,530,080 shares outstanding. The number of shares has decreased by -2.65% in one year.

Evofem Biosciences’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is 112.82%.

The current PE Ratio of Evofem Biosciences is 3.0. Evofem Biosciences’s PEG ratio is -0.03.

In the last 12 months, Evofem Biosciences had revenue of 20.18M and earned 391.00K in profits. Earnings per share was <0.01.

In the last 12 months, operating cash flow was -1.99M and capital expenditures -5.00K, giving a free cash flow of -2.00M billion.

Evofem Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Evofem Biosciences upcoming earnings date is Apr 30, 2026, Before Open (Confirmed).

Evofem Biosciences as a current ratio of 0.18, with Debt / Equity ratio of -94.86%

In the past 12 months, Evofem Biosciences has paid 2.00K in taxes.

Evofem Biosciences EV to EBITDA ratio is 32.19, with an EV/FCF ratio of -33.28.

Evofem Biosciences has $578.00K in cash and marketable securities with $65.87M in debt, giving a net cash position of -$65.29M billion.

Gross margin is 74.65%, with operating margin of 7.13%, and net profit margin of 1.94%.

The average price target for Evofem Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―